{"id":2312,"date":"2024-08-16T10:58:22","date_gmt":"2024-08-16T08:58:22","guid":{"rendered":"https:\/\/semmelweis.hu\/esk\/?p=2312"},"modified":"2025-11-28T10:59:35","modified_gmt":"2025-11-28T09:59:35","slug":"a-covid-19-xbb-1-5-oltoanyagok-eredmenyessegenek-elozetes-becslese-a-korhazi-kezelest-igenylo-megbetegedesek-megelozesevel-szemben","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/esk\/2024\/08\/16\/a-covid-19-xbb-1-5-oltoanyagok-eredmenyessegenek-elozetes-becslese-a-korhazi-kezelest-igenylo-megbetegedesek-megelozesevel-szemben\/","title":{"rendered":"A Covid-19 XBB.1.5 olt\u00f3anyagok eredm\u00e9nyess\u00e9g\u00e9nek el\u0151zetes becsl\u00e9se a k\u00f3rh\u00e1zi kezel\u00e9st ig\u00e9nyl\u0151 megbeteged\u00e9sek megel\u0151z\u00e9s\u00e9vel szemben"},"content":{"rendered":"
VEBIS* K\u00f3rh\u00e1zi vizsg\u00e1lat az olt\u00e1sok c\u00e9lcsoportj\u00e1ba tartoz\u00f3 feln\u0151ttek k\u00f6r\u00e9ben<\/strong>\u00a0
\nEur\u00f3pa, 2023. okt\u00f3ber \u2013 2024. janu\u00e1r<\/strong><\/h5>\n

Az \u00faj SARS-CoV-2 alvari\u00e1nsok megjelen\u00e9se miatt tov\u00e1bbra is kiemelt szerepe van az olt\u00f3anyagok fejleszt\u00e9s\u00e9nek a Covid-19 megbeteged\u00e9sek kock\u00e1zat\u00e1nak cs\u00f6kkent\u00e9s\u00e9ben. Az Eur\u00f3pai Gy\u00f3gyszer\u00fcgyn\u00f6ks\u00e9g ez\u00e9rt 2023. augusztus \u00e9s okt\u00f3ber k\u00f6z\u00f6tt enged\u00e9lyezte a friss\u00edtett \u00f6sszet\u00e9tel\u0171, XBB.1.5 alvari\u00e1ns elleni Covid-19 v\u00e9d\u0151olt\u00e1sokat. Jelen tanulm\u00e1ny c\u00e9lja annak meghat\u00e1roz\u00e1sa, hogy ezek az olt\u00f3anyagok milyen m\u00e9rt\u00e9k\u0171 v\u00e9delmet ny\u00fajtottak a s\u00falyos lefoly\u00e1s\u00fa, k\u00f3rh\u00e1zi ell\u00e1t\u00e1st ig\u00e9nyl\u0151 Covid-19 megbeteged\u00e9sekkel szemben.<\/p>\n

A vizsg\u00e1latot teszt-negat\u00edv m\u00f3dszertannal \u00e9s eset-kontroll elrendez\u00e9ssel v\u00e9gezt\u00fck 2023. okt\u00f3ber \u00e9s 2024. janu\u00e1r k\u00f6z\u00f6tt a 18 \u00e9ves \u00e9s id\u0151sebb, s\u00falyos akut leg\u00fati megbeteged\u00e9ssel k\u00f3rh\u00e1zi ell\u00e1t\u00e1sban r\u00e9szes\u00fcl\u0151 feln\u0151ttek k\u00f6r\u00e9ben. Az el\u0151zetes becsl\u00e9sekkel a frissen adapt\u00e1lt XBB.1.5 vakcin\u00e1k v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9g\u00e9t (VE) m\u00e9rt\u00fck a laborat\u00f3riumi (RT-PCR) m\u00f3dszerrel meger\u0151s\u00edtett SARS-CoV-2 fert\u0151z\u00e9s miatti k\u00f3rh\u00e1zi kezel\u00e9s megel\u0151z\u00e9s\u00e9ben.<\/p>\n

Eredm\u00e9nyeink szerint az olt\u00e1s csaknem fel\u00e9re cs\u00f6kkentette (VE = 49%) a Covid-19 miatti k\u00f3rh\u00e1zi kezel\u00e9sek es\u00e9ly\u00e9t az olt\u00e1s c\u00e9lcsoportjaiba tartoz\u00f3 szem\u00e9lyek k\u00f6r\u00e9ben. A legmagasabb v\u00e9detts\u00e9get az olt\u00e1s bead\u00e1s\u00e1t k\u00f6vet\u0151 14\u201329 nap k\u00f6z\u00f6tt m\u00e9rt\u00fck, ekkor a VE 69% volt, \u00e9s 60\u2013105 nap eltelt\u00e9vel is 40%-os v\u00e9delmet biztos\u00edtott. K\u00fcl\u00f6n\u00f6sen figyelemre m\u00e9lt\u00f3, hogy a 65 \u00e9v feletti korcsoportban az els\u0151 h\u00f3napban m\u00e9rt VE a 70%-ot is meghaladta.<\/p>\n

Az adapt\u00e1lt XBB.1.5 olt\u00f3anyagok az els\u0151 3,5 h\u00f3napban jelent\u0151s v\u00e9delmet ny\u00fajtottak a s\u00falyos lefoly\u00e1s\u00fa Covid-19 ellen, k\u00fcl\u00f6n\u00f6sen az id\u0151sebb koroszt\u00e1lyban. Az eredm\u00e9nyess\u00e9g azonban az id\u0151 el\u0151rehaladt\u00e1val fokozatosan cs\u00f6kkent, ami t\u00f6bb t\u00e9nyez\u0151vel is magyar\u00e1zhat\u00f3, p\u00e9ld\u00e1ul a v\u00e9detts\u00e9g lass\u00fa cs\u00f6kken\u00e9s\u00e9vel vagy a cirkul\u00e1l\u00f3 SARS-CoV-2 alvari\u00e1nsok v\u00e1ltoz\u00e1saival.<\/p>\n

    \n
  1. \u00e1bra: <\/strong>A Covid-19 XBB.1.5 olt\u00f3anyagok el\u0151zetes v\u00e9d\u0151olt\u00e1s-eredm\u00e9nyess\u00e9ge a k\u00f3rh\u00e1zi kezel\u00e9st ig\u00e9nyl\u0151 megbeteged\u00e9sek megel\u0151z\u00e9s\u00e9ben az olt\u00e1si c\u00e9lcsoportokba tartoz\u00f3 feln\u0151ttek k\u00f6r\u00e9ben, VEBIS K\u00f3rh\u00e1zi h\u00e1l\u00f3zat, Eur\u00f3pa, 2023. okt\u00f3ber \u2013 2024. janu\u00e1r<\/strong><\/span><\/li>\n<\/ol>\n

    \"\"<\/p>\n

    Forr\u00e1s: Influenza Resp Viruses, Volume: 18, Issue: 8, First published: 15 August 2024, DOI: (10.1111\/irv.13360) publik\u00e1ci\u00f3 1. \u00e1br\u00e1ja alapj\u00e1n SE ESK saj\u00e1t szerkeszt\u00e9s<\/span><\/p>\n

    \u00a0<\/strong><\/p>\n

    Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024<\/strong><\/h3>\n

    Antunes L <\/em>(Epiconcept, Paris, France)
    \nOroszi B <\/em>(National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest)
    \nT\u00fari G <\/em>(National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest)
    \nand the European Hospital Vaccine Effectiveness Group<\/em><\/p>\n

    Abstract<\/strong><\/h5>\n

    We conducted a multicentre test-negative case\u2013control study covering the period from October 2023 to January 2024 among adult patients aged \u2265\u200918\u2009years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14\u201329\u2009days and 40% at 60\u2013105\u2009days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5\u2009months post vaccination, with VE\u2009>\u200970% in older adults (\u2265\u200965\u2009years) up to 1\u2009month post vaccination.<\/p>\n

    * Vaccine Effectiveness, Burden and Impact Studies<\/span><\/p>\n

    Antunes L, Mazagatos C, Mart\u00ednez-Baz I, Naesens R, Borg ML, Petrovi\u0107 G, Fatukasi T, Jancoriene L, Machado A, Oroszi B, Husa P, Lazar M, D\u00fcrrwald R, Howard J, Melo A, P\u00e9rez-Gimeno G, Castilla J, Bernaert E, D\u017eiugyt\u0117 A, Makari\u0107 ZL, Fitzgerald M, Mickien\u0117 A, Gomez V, T\u00fari G, Sou\u010dkov\u00e1 L, Marin A, Tolksdorf K, Nicolay N, Rose AMC; European Hospital Vaccine Effectiveness Group. Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024. Influenza Other Respir Viruses. 2024 Aug;18(8):e13360. doi: 10.1111\/irv.13360. PMID: 39145535; PMCID: PMC11325250.<\/span><\/p>\n

    https:\/\/pubmed.ncbi.nlm.nih.gov\/39145535\/<\/strong><\/a><\/p>\n

    \u00a0<\/p>\n

    K\u00e9sz\u00edtette az \"\"\u00a0<\/em><\/span><\/p>\n

    \"\"<\/em>RRF-2.3.1-21-2022-00006\u00a0<\/span><\/span><\/p>\n

    \"\"<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

    VEBIS* K\u00f3rh\u00e1zi vizsg\u00e1lat az olt\u00e1sok c\u00e9lcsoportj\u00e1ba tartoz\u00f3 feln\u0151ttek k\u00f6r\u00e9ben\u00a0 Eur\u00f3pa, 2023. okt\u00f3ber \u2013 2024. janu\u00e1r Az \u00faj SARS-CoV-2 alvari\u00e1nsok megjelen\u00e9se miatt tov\u00e1bbra is kiemelt szerepe van az olt\u00f3anyagok fejleszt\u00e9s\u00e9nek a Covid-19 megbeteged\u00e9sek kock\u00e1zat\u00e1nak cs\u00f6kkent\u00e9s\u00e9ben. Az Eur\u00f3pai Gy\u00f3gyszer\u00fcgyn\u00f6ks\u00e9g ez\u00e9rt 2023. augusztus \u00e9s okt\u00f3ber k\u00f6z\u00f6tt enged\u00e9lyezte a friss\u00edtett \u00f6sszet\u00e9tel\u0171, XBB.1.5 alvari\u00e1ns elleni Covid-19 v\u00e9d\u0151olt\u00e1sokat. Jelen tanulm\u00e1ny c\u00e9lja …<\/p>\n","protected":false},"author":102284,"featured_media":2313,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-2312","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cikk-osszefoglalok"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/users\/102284"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/comments?post=2312"}],"version-history":[{"count":2,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2312\/revisions"}],"predecessor-version":[{"id":2315,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/2312\/revisions\/2315"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media\/2313"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media?parent=2312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/categories?post=2312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/tags?post=2312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}